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Abstract--Sphingosine kinase 1 (SphK1) knockout mice are protected against pulmonary 
hypertension and expression levels of the enzyme are increased in the lungs of pulmonary 
arterial hypertensive (PAH) patients.  Moreover, sphingosine 1-phosphate can promote 
vascular remodeling/vasoconstriction in rodent and human pulmonary arterial smooth 
muscle cell models.  Therefore, SphK1 might be a novel target for treatment of PAH.  
However, in our opinion more refined strategies to target SphK1 are needed because this 
enzyme is protective against endothelial dysfunction and can become resistant to SphK1 
inhibitors in vascular smooth muscle, thereby potentially limiting effectiveness in PAH.  
In addition, SphK1 is involved in maladaptive hypertrophy and we propose that heart 
failure might be an additional direct target for therapeutic intervention with SphK1 
inhibitors.  
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Pulmonary Arterial Hypertension and Sphingosine 1-Phosphate 
Pulmonary arterial hypertension (PAH) affects 15-50 people/million and is 
characterised by elevated mean arterial blood pressure, shortness of breath, fatigue, 
dizziness, chest pain and edema.  PAH can lead to reduced blood flow to the heart, 
cardiac hypertrophy and heart failure.  PAH affects small pre-capillary arteries in the lung 
where there is enhanced vasoconstriction and vascular remodelling (see Glossary) with 
an underlying inflammation [1].  Treatment is aimed at enhancing pulmonary 
hemodynamics, exercise tolerance and life quality.  Drugs used to treat PAH are 
vasodilators including prostacyclin analogues, endothelin receptor antagonists and 
phosphodiesterase 5 inhibitors.  Combination therapies with these agents has significantly 
improved life expectancy from ~ 3 years at diagnosis to 5-7 years [1]. Nevertheless 
progressive vascular and ventricular remodeling still occurs leading to cardiac 
hypertrophy/heart failure and death.  Therefore, there is still an unmet medical need and 
recent findings suggest that sphingosine 1-phosphate (S1P) might be a potential novel 
target for clinical intervention in PAH.  This is exemplified by the role of sphingosine 
kinase 1 (SphK1, which catalyses the formation of S1P) and the S1P2 receptor (which is 
specifically activated by binding of S1P) in vascular remodeling and vasoconstriction in 
rodent models (Figure 1).  In addition, SphK1 and S1P are linked with signaling networks 
that involve gene products that are significantly up-regulated in human PAH, such as the 
Receptor for Advanced Glycation End products (RAGE) [2] and Signal Transducer 
Activator of Transcription 3 (STAT3) [3]. The enzyme is also potentially linked with 
down-regulation of Bone Morphogenetic Protein Receptor type II (BMPR2) [4], where 
inactivating mutations in the BMPR2 gene are associated with familial hypertension [5]. 
The overlap of SphK1 signaling with known PAH susceptibility gene products provides 
additional support for the idea that the enzyme could be considered as a novel target for 
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therapeutic intervention in PAH.  However, targeting SphK1 might also enhance 
endothelial dysfunction [6], thereby potentially limiting effectiveness of SphK1 inhibitors 
in reducing vascular smooth muscle contractility/remodeling and blood pressure in 
humans.  A plausible reason for this might be that SphK1 inhibitors reduce the levels of 
vasorelaxants released from the endothelium that function to oppose 
vasoconstriction/vascular remodeling.  SphK1 inhibitors can also induce the proteasomal 
degradation of SphK1 in human pulmonary arterial smooth muscle (PASMC) cells and 
cancer cells [7-9], which probably underlies some of the major effects of these inhibitors.  
However, in certain cases, as will be discussed, SphK1 can become resistant to SphK1 
inhibitors [7, 10] thereby potentially limiting the effectiveness of the latter in the 
treatment of PAH.  To date, various data supporting a role for SphK1 has been obtained 
using different animal models of pulmonary hypertension, some of which reflect severe 
PAH (e.g. Sugen5416 rat model).  Arguably data obtained using such severe models of 
PAH are likely more informative than models that do not fully recapitulate human 
disease, in terms of predicting translational potential of SphK1 inhibitors to man.  In 
addition, studies on SphK1 and S1P, in terms of regulating vascular tone, use different 
vascular sources from rodents and it is recognized that there are differences between the 
vascular smooth muscle in the pulmonary circulation compared with the systemic 
circulation i.e. different developmental origin, which places some constraints on 
extrapolation of the findings to human PAH. 
 
Sphingosine kinase 1 and Hypertension 
The sphingosine kinases (two isoforms, SphK1 and SphK2) phosphorylate 
sphingosine to produce the bioactive lipid, S1P.  Human and mouse SphK1 and SphK2 are 
encoded by distinct genes and the enzymes exhibit different subcellular localisation and 
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biochemical properties to regulate both overlapping and non-overlapping signaling 
pathways [11].  S1P can either be exported from cells and bind to a family of five S1P-
specific G protein coupled receptors (S1P1-5) [12, 13] or can interact with intracellular 
proteins, such as human HDAC-1/2 [14] to induce biological and cellular regulation.    
There is a growing body of evidence that clearly supports a significant role for SphK1 
and S1P in the pathogenesis of hypertension.  For instance, hypoxia, which induces 
pulmonary hypertension, increases SphK1 and SphK2 mRNA transcript levels in human 
PASMC [15].  Indeed, the SphK1 gene promoter has two hypoxia-inducible factor 
responsive elements (hypoxia-inducible factor 1D (HIF1Į) and hypoxia inducible factor 
2DHIF2Į)) [16]. Given the changes in SphK1 expression in human PASMC under 
chronic hypoxic conditions, we had previously proposed that this might be a contributing 
factor to the vascular remodeling in PAH [15].  A subsequent study reported increased 
SphK1 protein expression in the lungs and increased SphK1 protein and mRNA transcript 
levels in PASMC from patients with PAH [17].  Increased SphK1 protein expression levels 
were also found in the lungs of hypoxic-induced pulmonary hypertensive rats and mice 
compared with normoxic animals [17]. Similarly, elevated levels of S1P were found in the 
lungs of patients with PAH and in pulmonary arteries of hypoxic-induced pulmonary 
hypertensive rats and mice [17]. In contrast, no changes in SphK2 protein expression were 
detected in the lungs/PASMC from PAH patients or in hypoxic treated rodent models 
compared with healthy patients or normoxic animals respectively [17].  Moreover, SphK1
-/-
 
mice were shown to exhibit lower right ventricular systolic pressure (RVSP), decreased 
right ventricular hypertrophy (RVH) and less severe pulmonary vascular remodeling in 
response to hypoxia, while the development of pulmonary hypertension was not mitigated 
in SphK2
-/-
 mice [17].  These findings suggest that SphK1, but not SphK2, is involved in 
the development of pulmonary hypertension in mice and possibly humans.  The authors 
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also used a pharmacological inhibitor of S1P synthesis, SKi (SKI-II, 4-[[4-(4-
chlorophenyl)-2-thiazolyl]amino]-phenol) [17], which inhibits both SphK1 and SphK2 
activity. When administered to rats (10 mg/kg body weight, i/p), SKi prevented the 
development of hypoxia-dependent pulmonary hypertension, as assessed by reduced 
RVSP, RVH, and pulmonary vascular remodeling [17]. Conversely, heterozygote mice for 
the Sgpl1 gene, encoding S1P lyase which irreversibly cleaves S1P, exhibited increased 
lung S1P levels and elevated RVSP and RVH, which led to increased hypoxic-dependent 
pulmonary vascular remodeling compared with wild type (WT) mice [17].  Such opposing 
regulation of S1P levels by either reducing SphK1 activity (decreased S1P levels) or S1P 
lyase activity (increased S1P levels) is consistent with S1P being a key mediator in 
regulating vascular remodeling associated with changes in the proliferation of human 
PASMC.  Indeed, the over-expression of wild type SphK1, which is fully catalytically 
competent, was reported to enhance human PASMC proliferation whereas a dominant 
negative kinase inactive form of SphK1 (G82D mutation) reduced PASMC proliferation 
[17].  Furthermore, PASMC from SphK1
-/- 
mice exhibited lower proliferation rates in 
response to chronic hypoxia compared with cells from WT mice [17], suggesting that S1P 
promotes PASMC proliferation in this mouse model.   
One possible molecular mechanism by which SphK1 might regulate human PASMC 
proliferation and therefore vascular remodeling, involves so-called inside-out signaling 
[18] where S1P formed by SphK1 is released from human PASMC to act upon S1P 
receptors, thereby promoting proliferation in an autocrine manner [17] (Figure 1).  This 
model is supported by evidence showing that siRNA knockdown of S1P2 expression or 
S1P2 antagonism with JTE-013 (which is also a competitive antagonist of S1P4 [19]) 
ablated the S1P-stimulated proliferation of human PASMC [17].  This report suggested 
that S1P/S1P2 uses ERK-1/2 and STAT3 signaling to promote human PASMC 
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proliferation [17], and which is significant as STAT3 activation has been shown to be 
involved in pro-survival and proliferative pulmonary vascular phenotypes associated with 
human PAH [3, 20, 21].  Finally, the S1P2/4 antagonist, JTE-013 (8 mg/kg body weight, 
i/p) prevented and reversed pulmonary hypertension in the hypoxic mouse model [17], 
thereby confirming that S1P2 is involved in S1P-stimulated vascular remodeling in this 
model.   
Increased SphK1 and SphK2 protein expression together with elevated plasma S1P 
levels were also detected in remodelled pulmonary arteries of patients with idiopathic 
pulmonary arterial hypertension (IPAH) and this has been recapitulated in the 
Sugen5416/hypoxia/normoxia (Su/Hx/Nx PAH) rat model of occlusive pulmonary 
hypertension [22].  A role for SphK1 in this rat model was demonstrated using the 
selective SphK1 inhibitor, SLP7111228 (10 mg/kg administered i/p), which reduced 
plasma S1P levels and the percentage of occluded pulmonary arteries and increased the 
percentage of non-occluded pulmonary arteries.  These results suggest that SphK1 
promotes occlusive pulmonary arteriopathy in severe PAH.  In addition, the increase 
right ventricular internal diameter (RVID) observed in Su/Hx/Nx PAH rats was 
decreased by the SphK1 inhibitor [22].  Improved cardiovascular function with the SphK1 
inhibitor was also observed as evidenced by increased cardiac index (CI) and reduced 
total pulmonary artery resistance index (TPRI).  However, this was not accompanied 
by reduced RVSP or RVH, and chronic SphK1 inhibition had no effect on systemic arterial 
pressure and heart rate [22]. This is accounted for by the authors as being due to a direct 
beneficial effect of the SphK1 inhibitor on maladaptive hypertrophy [22].  
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RAGE and SphK1 and PAH 
Receptor for Advanced Glycation End-products (RAGE), which is a member of the 
immunoglobulin family, can activate STAT3 and induce down-regulation of peroxisome-
proliferator-activated receptor gamma (PPARJ) and BMPR2 [2].  This results in increased 
vascular smooth muscle proliferation and development of a PAH phenotype [2].  RAGE is 
important because it is one of the most up-regulated genes in PAH [23].  Ligands of RAGE 
include S100A4 which belongs to the family of EF-hand calcium-binding proteins [24] and 
inhibition of RAGE reverses the PAH phenotype in monocrotaline- and Sugen-induced 
rodent models [2].  Moreover, treatment of rat mesanglial cells with low concentrations of 
advanced glycation end-products (AGE) results in increased SphK activity and S1P 
production that promotes cell proliferation [25].  Therefore, we propose that the ability of 
AGE to stimulate SphK and S1P formation might provide a mechanism by which RAGE 
could potentially use S1P and S1P2 to promote STAT3 activation and thereby induce 
down-regulation of BMPR2 and PPARJ, a key process in the development of the PAH 
phenotype [2].  This possibility requires further investigation. 
 
SphK1 and miR-124 and miR-21 
There is also interaction between miRNA and SphK1, thereby linking the enzyme with 
a major disease-forming mechanism in PAH.  For instance, miR-124 inhibits migration and 
invasion of ovarian cancer cells by down-regulating SphK1 and reduces gastric cancer cell 
proliferation also by targeting SphK1 [26, 27].  miR-124, which regulates NFATc1, 
CAMTA1 (calmodulin-binding transcription activator 1) and PTBP1 (polypyrimidine 
tract-binding protein 1) to reduce nuclear factor of activated T cells (NFAT)-dependent 
transcription, is down-regulated in human PASMCs and mouse lungs under hypoxic 
conditions [28].  This is significant, as overexpression of miR-124 inhibits human PASMC 
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proliferation [28]. Therefore, down-regulation of miR-124 in PAH might provide an 
explanation for the increased expression of SphK1, and the related effects of the enzyme 
on the PAH phenotype.  In addition, transforming growth factor-E-SphK1/S1P signaling 
involving S1P2 upregulates miR-21 to promote fibrosis [29].  Moreover, the inhibition of 
miR-21 prevents/reverses pulmonary hypertension in hypoxic-treated mice [30].  miR-21 
also enhances human PASMC proliferation and down-regulates BMPR2 [30], thereby 
potentially linking SphK1/S1P via miR-21 with pulmonary hypertension. 
 
Sphingosine 1-phosphate and Vascular Smooth Muscle Contractility. 
 There is substantial evidence to suggest that SphK1 and S1P also play a significant 
role in regulating vascular contractility.  In this regard, the basilar artery from Sphk1
í/í
 
mice exhibits weaker vasoconstriction in response to KCl or S1P or U46619 (TxA2 
receptor agonist) compared with the arteries of WT or Sphk2
í/í
mice [31].  One mechanism 
by which S1P might induce contraction of vascular smooth muscle appears to involve 
regulation of store-operated calcium channels (SOC). Specifically, angiotensin II (Ang-II) 
(AT1A receptor-mediated) has been reported to induce calcium entry into rat vascular 
smooth muscle cells [32] and this involves an early inositol 1,4,5-trisphosphate (IP3)-
dependent mobilisation of Ca
2+
 from intracellular stores, evidenced by inhibition of this 
phase of Ca
2+
 with the phospholipase C inhibitor, U73122.  A second sustained 
extracellular Ca
2+
 influx through SOC occurs and this can be reduced by pharmacological 
inhibition of SphK1 or SOC (SOC inhibitor, SKF96365).  The SOC inhibitor was not 
effective in vascular smooth muscle cells derived from SphK1
-/-
 mice suggesting that 
Sphk1 is an up-stream regulator of SOC [32]. Intracellular S1P was also reported to 
mediate an effect on SOC-dependent Ca
2+
 influx independently of S1P receptors as the 
S1P1/3 receptor antagonist (VPC23019) and S1P2/4 antagonist (JTE-013) failed to modify 
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the response [33].  Taken together with other findings described above, S1P appears to act 
both extracellularly (via S1P2) and intracellularly (via SOC) to regulate blood pressure 
changes. 
More recent studies have questioned the role of SphK1 and S1P in promoting vascular 
remodeling, while maintaining some agreement concerning vascular smooth muscle 
contractility.  In this regard, chronic treatment with Ang-II increased SphK1 mRNA 
expression in thoracic and abdominal aorta and mesenteric arteries of mice and increased 
SphK1 protein expression was detected in aorta and mesenteric artery homogenates [6].  In 
addition, S1P levels were increased in the plasma of Ang-II-treated WT but not Sphk1
í/í 
mice [6]. Of relevance, Sphk1
í/í 
mice developed significantly less severe Ang II-induced 
hypertension and cardiac hypertrophy compared to WT mice, suggesting a role for SphK1 
in Ang II-induced hypertension [6].  However, fibrotic changes in the heart as well as 
intima-media thickness of cardiac arteries were similar between WT and Sphk1
í/í 
mice, 
suggesting that SphK1 is not involved in promoting vascular remodeling in this model [6]. 
These findings are consistent with the observation that the selective and potent SphK1 
inhibitor, PF-543 (at nM concentrations) had no effect on vascular remodeling in a mouse 
hypoxic model of pulmonary hypertension [33].  Of note, chronic Ang-II-induced 
hypertensive Sphk1
í/í
 mice exhibit less aortic and mesenteric artery contractility in 
response to phenylephrine or noradrenaline, suggesting that SphK1 also functions down-
stream of D1 adrenoceptors [6].  In addition, S1P2 expression was increased in the thoracic 
aorta in this model of hypertension [6], thereby potentially linking changes in SphK1 
expression with inside-out signaling by S1P at S1P2 receptors to promote 
vasoconstriction and increased blood pressure.  Indeed, Ang II-induced contraction of 
mesenteric arteries was reduced by the S1P2/4 antagonist, JTE-013 and by the SphK1 
inhibitor, PF-543.  The authors also showed lower cardiac hypertrophy and changes in 
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aortic superoxide formation after Ang II infusion in Sphk1
í/í
 mice; this is significant as 
superoxide can increase endothelial dysfunction [6].  In this regard, NADPH oxidase 
expression in the aorta and mesenteric arteries was increased in hypertensive Sphk1
í/í 
mice 
compared with hypertensive WT mice [6].   
There is also some controversy as to whether S1P2 regulates contractile tone.  For 
instance, S1P was reported to induce basilar artery contraction in rats and in WT and S1P2 
null mice, but this was severely reduced in S1P3 null mice, suggesting a role for S1P3 
rather than S1P2.   In contrast, vasoconstriction in response to U46619 or to endothelin-1 
was similar in vessels from WT, S1P2 null and S1P3 null mice, suggesting that these 
receptors are not involved in the effect of U46619 and endothelin-1 [34].  In addition, this 
study revealed that JTE-013 could not only inhibit S1P-induced vasoconstriction, but also 
KCl-, U46619- and endothelin-1-induced constriction, which persisted in S1P2 null mice 
[34] and which might suggest ablation of S1P4 signaling.  The potential effect of the 
endothelium on vasoconstrictor response was demonstrated by use of the S1P1/3 receptor 
antagonist VPC23019, which enhanced S1P stimulated constriction, possibly as a 
consequence of blocking S1P1-induced nitric oxide generation in the endothelium.  In this 
regard, S1P binding to S1P1 activates endothelial nitric oxide synthase (eNOS) in 
endothelial cells [36].  Finally, the S1P4 receptor agonist VPC23153 induced enhanced 
contraction of isolated pulmonary arteries from chronically hypoxic rats [36]. S1P4 was 
detected in both normotensive and hypertensive pulmonary arteries, suggesting that post-
receptor signaling from S1P4 might be enhanced under hypertensive conditions, rather than 
changes in responsiveness being due to S1P4 expression. Since S1P-induced 
vasoconstriction was not reduced by VPC23019 or JTE-013 in this model, it appears that 
S1P2 and S1P3 do not play a role in the vasoconstrictor response of pulmonary vessels in 
rats [36].   
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In order to be able to translate these findings into the clinic, it is important that S1P 
receptor profiles of PAH patients be determined.  Furthermore, identification and 
characterization of the S1P receptor involved in promoting vasoconstriction will be 
required.  In our opinion, S1P2 is likely to be the key receptor, given that it is up-regulated 
in the thoracic aorta in mouse models of Ang II-stimulated pulmonary hypertension [6] and 
in patients with IPAH [17].  However, this hypothesis requires further investigation. S1P2 
antagonists would need to be very selective for S1P2 and lack affinity for S1P1 or S1P3, as 
these latter receptors have been implicated in promoting endothelial function and 
vasodilation and therefore their blockade by an antagonist would potentially worsen 
hypertension.  A summary of the role of rodent and human SphK1/S1P receptors in 
vascular smooth muscle contractility is presented in Figure 2. 
There is also a role for S1P in other forms of hypertension.  In this regard, sinusoidal 
vasoconstriction has an important role in portal hypertension and in this case, hepatic 
stellate cells function in a contractile manner promoted by S1P to enhance portal vein 
pressure in rat livers [37].  Administration of the S1P2/4 receptor antagonist, JTE-013 (1 
mg/kg, i/v) to bile duct-ligated rats reduced portal vein pressure by 24%, and had no effect 
in sham operated rats [37] or on mean arterial pressure in bile duct ligated rats.  Rho kinase 
activity was increased in livers of bile duct-ligated rats and this was reduced by infusion of 
JTE-013 [37].  Moreover, S1P2 mRNA expression was increased in livers of bile duct-
ligated mice compared with sham-operated mice [37], suggesting that this receptor might 
mediate the effects of S1P.  In addition, Rho kinase activity was reduced in S1P2
-/- 
mice 
subjected to bile duct ligation compared to wild type mice and the effects of the S1P2 
antagonist were lost in the S1P2
-/-
 mice.   
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SphK1 and Endothelial Cell Function 
S1P has an important role in the developmental of the endothelium and formation of 
blood vessels.  Thus, VEGF promotes sprouting of endothelial cells to produce capillary 
tubes that are subsequently acted on by S1P/S1P1, which promotes stabilization of VE-
cadherin at endothelial junctions [38, 39].  In addition.  S1P1 responds to laminar shear 
stress to confer flow-dependent signaling in endothelial cells both in vitro and in vivo, and 
which stabilizes blood vessel development and homeostasis [40].  Significantly, S1P also 
exerts a protective role in endothelial cells by binding to S1P1/3 receptors to promote eNOS 
signaling [35].   
The therapeutic potential of SphK1 inhibitors is likely to be compromised somewhat 
by the protective role of SphK1 against endothelial cell dysfunction.  Thus, inhibition of 
endothelial SphK1 could potentially worsen endothelial dysfunction and thereby reduce the 
effectiveness of SphK1 inhibition in blocking vasoconstriction.  The protective role of 
SphK1 is exemplified by studies using aortic rings isolated from Ang II-induced 
hypertensive Sphk1
-/-
 mice, which exhibit reduced vasorelaxation in response to 
acetylcholine compared to WT mice, suggesting that release of nitric oxide is impaired by 
loss of SphK1 [6].  In addition, low plasma S1P levels significantly correlated with 
impaired endothelial function in the Ang II-induced hypertensive mouse model [6]. 
Additionally, anandamide has been shown to induce relaxation of rat coronary arteries via 
an endothelium-dependent mechanism that involves SphK1 and S1P3 thereby providing 
additional evidence for activation of SphK1 and release of S1P from endothelial cells, 
which can then bind S1P3 in an autocrine manner to induce vasorelaxation [41].  Of note, 
genetic deletion of the Sphk1 gene in Ang II-induced hypertensive mice had no significant 
effect on intima medial hypertrophy, suggesting that the observed impairment in 
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endothelial function in Sphk1
-/-
 mice might explain why loss of this gene has no effect on 
vascular remodeling in this model [6].  
Further evidence to support a role for SphK1 in protecting endothelial cell dysfunction 
has become evident in studies on Nogo B.  Nogo-B inhibits serine palmitoyltransferase, 
which is the rate-limiting enzyme of de novo ceramide synthesis. Ceramide can be 
subsequently converted to sphingosine and S1P in mouse endothelial cells [42].  Indeed, 
mice deficient in Nogo B are hypotensive, resistant to angiotensin II-induced hypertension 
and exhibit preserved endothelial-dependent NO release [42].  This is accounted for, by 
increased endothelial S1P-S1P1-eNOS signaling (due to removal of the inhibitory effect of 
Nogo B on serine palmitoyltransferase), which promotes vasodilation.  Indeed, this 
accounts for the hypotensive phenotype which can be reversed by pharmacological 
inhibition of serine palmitoyltransferase with myriocin [42].  In this regard, endothelial 
SphK1 is likely to play a significant role in producing S1P to preserve endothelial cell 
function and to reduce vascular contractility and vascular remodeling. However, this 
hypothesis remains to be validated.  A summary of the role of SphK1 in endothelial 
function is provided in Figure 2. 
 
Development of SphK1 Inhibitors for the Treatment of Pulmonary Arterial 
Hypertension? 
The opposing functions of SphK1 in endothelial versus smooth muscle cells might 
allow extracellular factors that regulate the enzyme to instigate coordinated regulation and 
communication between the two cell types.  However, the dual action of SphK1 might 
compromise the effect of SphK1 inhibitors in reducing blood pressure.  In our opinion, 
more refined strategies that spare endothelial SphK1 function are required for translation of 
SphK1 inhibitors to the clinic for treatment of PAH.  Human SphK1 exists as three N-
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terminal variants (SphK1a-c) encoded by the same gene [11].  Most studies have either 
focussed on SphK1a and/or have not defined the predominant isoform expressed in cell 
types studied.  However, if these isoforms are differentially expressed in vascular smooth 
muscle and endothelial cells then one might be able to produce isoform sub-type-selective 
SphK1 inhibitors that prevent vascular remodelling/vasoconstriction and spare the 
endothelial protective mechanism(s).  We propose that allosteric, rather than catalytic 
inhibitors might provide SphK1 isoform sub-type selectivity as these inhibitors could 
potentially target regulatory protein-protein interactions that exploit the N-terminal 
variation of the SphK1 sub-types.  
It may also be possible to exploit the two mechanisms by which SphK1 inhibitors 
affect SphK1 function.  First, SphK1 inhibitors can rapidly and reversibly inhibit catalytic 
activity [8].  Second, SphK1 inhibitors induce a longer term (e.g. 24 h) ubiquitin-
proteasomal degradation of SphK1 thereby substantially reducing expression of the 
enzyme in human PASMC [7-9, 43].  Both mechanisms might impact contractility and/or 
vascular remodeling, although proteasomal degradation of SphK1 might predominantly 
affect remodeling, given the protective effect of Sphk1 knockout on vascular remodeling in 
the hypoxic mouse model of pulmonary hypertension to reduce blood pressure and RV 
hypertrophy [17].   In addition, distinct SphK1 sub-types exhibit differential susceptibility 
to inhibitor-induced proteasomal degradation [7, 10] and we propose that this might be 
exploitable to preserve endothelial function, while inhibiting vasoconstriction. Further 
investigation in these areas is required to help to elucidate these hypotheses. 
Certain SphK1 inhibitors can be considered direct inducers of the proteasomal 
degradation of SphK1. For instance, PF-543 binds to SphK1 to induce a conformation that 
promotes its proteasomal degradation [9].  This is based on the strong correlation between 
the concentrations of inhibitor required to induce proteasomal degradation in human 
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PASMC with the Ki for inhibition of the catalysis of S1P formation by purified human 
SphK1 [43].  Another direct SphK1 inhibitor, RB-005 (10 mg/kg i/v) [33] has been found 
to induce the proteasomal degradation of SphK1 in human PASMC in vitro and in 
pulmonary vessels from mice (10 mg/kg, i/v) exposed to normoxia, but failed to reduce 
SphK1 expression in the pulmonary vessels of mice treated with hypoxia for 3 weeks [33].  
In addition, RB-005 had no significant inhibitory effect on RVP or vascular remodeling in 
hypoxic-treated mice [33], suggesting that the failure to remove SphK1 by proteasomal 
degradation from these hypoxic vessels prevents the inhibitor from reversing or blocking 
vascular remodeling.   In addition, a weak inhibitor of SphK1, such as SKi, has been 
shown to induce accelerated proteasomal degradation of SphK1 via activation of the 
proteasome in human prostate cancer cells [7].   This is an example of an indirect inducer 
of the proteasomal degradation of SphK1.  Indeed, we have shown that proteasomal 
degradation of SphK1 by indirect inducers occurs via additional inhibition of 
dihydroceramide desaturase (Degs1) (an enzyme within the de novo ceramide synthesis 
pathway).  In this regard, SKi inhibited Degs1 activity in Jurkat and prostate cancer cells 
[44, 45].  We have proposed that Degs1 might function to limit protein degradation flux 
through the proteasome [44] and therefore its inhibition by SKi promotes proteasomal 
degradation of SphK1.  Moreover, another study reported that SKi could prevent the 
development of hypoxic-dependent pulmonary hypertension in mice, as assessed by 
reduced RVSP, RVH and pulmonary vascular remodelling [17].   Therefore, it is possible 
that an indirect inducer effect of SKi (i.e. via Degs1) on SphK1 degradation might bypass 
conformation-specific changes in SphK1 that could confer resistance to other direct 
inducers (e.g. RB-005).  This may explain why the previous study [17] was able to 
recapitulate the genetic loss of SphK1 using SKi, which led to reduced RVSP, RVH and 
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pulmonary vascular remodeling in hypoxic mice. However, robust testing is warranted to 
further address these questions. 
The resistance of SphK1 to direct inducers as seen for RB-005 in hypoxic-treated 
mice [33], might also occur in other models of pulmonary hypertension, with observed 
differences in the modulation of vascular remodeling and blood pressure. For example, 
SphK1 is regulated by acetylation [46] and this can occur at the same lysine residues as 
ubiquitination.  Aberrant acetylation of SphK1 in PAH could potentially confer resistance 
to SphK1 inhibitor-induced proteasomal degradation and is thus, worthy of further study.   
The allosteric inhibitor of SphK1, (S)-FTY720 vinylphosphonate has been found to 
induce proteasomal degradation of human SphK1 [8], thereby producing an alternative 
conformation which appears to bypass resistance to proteasomal degradation in human 
androgen-independent prostate cancer cells [8].  A summary of the regulation of SphK1 by 
proteasomal degradation and the impact on pulmonary hypertension is presented in Figure 
3.  The major conclusion from the findings described above is that it is important to 
consider the effect of catalytic and allosteric SphK1 and Degs1 inhibitors on the ubiquitin-
proteasomal degradation status of SphK1 when evaluating the translational potential of 
these inhibitors for PAH.  It is also important to establish whether SphK1 isoforms in 
human endothelial and vascular smooth muscle cells are differentially expressed as this 
might inform on targeting strategies designed to inhibit vasoconstriction/vascular 
remodeling and preserve endothelial function. 
 
SphK1 Inhibitors and Cardiac Hypertrophy 
Maladaptive hypertrophy leads to RV failure in the heart, the major cause of mortality 
in PAH patients [47].  Apoptosis has been shown to increase as RV function declines in 
monocrotaline treated rats [48] and pharmacologically-mediated reduction in RV 
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hypertrophy has been associated with decreased apoptosis in monocrotaline treated rats, as 
evidenced by measurement of an increased Bcl2/Bax ratio [49].  Moreover, increased RV 
hypertrophy proceeds from and correlates with elevated RV pressure. However, sustained 
RV pressure can exist in the absence of significant RV hypertrophy in a persistent model 
of pulmonary hypertension in mice [51].  Administration of PF-543 (1 mg/kg, i/v) in the 
mouse hypoxic model of pulmonary hypertension has been shown to reduce RV 
hypertrophy (without changes in blood pressure), presumably via direct action on the 
heart, although this remains to be demonstrated [33]. In this study, cardiomyocyte 
apoptosis was observed in RV sections from chronic hypoxic mice, suggesting deleterious 
progression of RV [33].  Chronic administration of PF-543 to mice reduced the apoptotic 
index [33] suggesting that the SphK1 inhibitor might be protective. Hypoxia also induced 
formation of ADP-ribosylated PARP in the right ventricle, which was completely blocked 
by chronic administration of PF-543 to mice [33] and which supports evidence of a 
substantial blockade of apoptosis.  Furthermore, the cardio-protective effect of PF-543 was 
associated with decreased pro-apoptotic p53 levels and increased pro-survival anti-oxidant 
nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) expression in the right ventricle [33].  
Indeed, pressure overload  has been found to induce p53 expression via a mechanism 
involving the transcription factor, HIF1Į; p53, in turn, was reported to inhibit 
angiogenesis by reducing HIF1Į levels in a negative feedback manner in severe transverse 
aorta restriction in wild type and p53 deficient mice [51]. This finding is interesting 
because it suggests that PF-543 reduces p53 expression levels in the right ventricle, which 
may lead to angiogenesis/new blood vessel formation, in turn, increasing re-oxygenation 
to the heart.  This might prevent development of maladaptive hypertrophy and 
subsequently apoptosis of cardiomyocytes.  This hypothesis requires further investigation.  
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 Cardiac S1P levels have also been shown to  increase in mice subjected to left anterior 
descending coronary ligation to induce post-myocardial infarction (MI).  This is associated 
with increased SphK1 and S1P1 expression, suggesting that MI can regulate transcriptional 
activity of the genes encoding these proteins [52].  In this study administration of PF-543 
(1 mg/kg, i/p) or FTY720 (1 mg/kg, i/p) reduced chronic cardiac inflammation and 
improved cardiac remodeling and dysfunction in vivo post-MI in mice [52].  FTY720 is 
converted to FTY720 phosphate, which is a S1P1 functional antagonist (see [11] for 
review) and FTY720 is also a SphK1 inhibitor [8]. These authors also showed that 
SphK1/S1P/S1P1-dependent STAT3 signaling and inflammation was modulated by 
FTY720, thereby reducing post-MI cardiac remodeling and dysfunction [52].  Therefore, 
SphK1 might participate in the chronic pro-inflammatory and fibrotic responses during the 
hypertrophic process that eventually leads to cardiomyocyte apoptosis and RV failure. 
Taken together with our findings on chronic hypoxic maladaptive hypertrophy, we 
propose that heart failure might be an additional target for therapeutic intervention with 
SphK1 inhibitors. However, these studies are preliminary, and further validation will be 
required prior to fully considering SphK1 as target to direct treatment of cardiac 
hypertrophy. A summary concerning the role of SphK1 in maladaptive hypertrophy is 
presented in Figure 4.   
The detrimental role of SphK1 in long term cardiac remodeling contrasts with its 
protective role in ischemia/reperfusion where there is a loss of pre-conditioning or an 
exacerbation of injury in ex-vivo hearts from Sphk1
-/-
 and Sphk2
-/-
 mice [53, 54].  In these 
models, ischemia promotes a rapid apoptotic/necrotic response that precedes longer term 
cardiac remodeling.  In addition, genetic loss of SphK1 in mice results in poor 
resuscitation after cardiac arrest and reduced survival post-resuscitation, but this could be 
reversed by S1P lyase inhibition with 2-acetyl-4-(tetrahydroxybutyl)imidazole (THI) and 
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was correlated with dihydroS1P rather than S1P levels [55].  These findings suggest a role 
for dihydroS1P in acute ischaemia [55].  The genetic loss of SphK1 and inhibition of S1P 
lyase results in alteration in S1P1 and S1P2 expression in the heart [55].  Such adaptive 
changes in S1P receptors as a possible consequence of altered S1P metabolism is an 
important cautionary consideration when evaluating findings from genetic loss of 
function studies.  
 
Concluding Remarks 
There are a number of questions concerning the role of SphK1/S1P in PAH (see 
Outstanding Questions and Box 1).  More emphasis should be placed on establishing 
functional interaction between SphK1 signaling pathways and other pathways linked with 
PAH, such as BMPR2, RAGE and miRNA regulation.  This approach might offer the 
possibility to bridge the experimental data with a solid rationale to support the use of 
SphK1 inhibitors in patients.  We suggest that novel strategies will be necessary to produce 
inhibitors  presumably allosteric -- that induce a conformational change in SphK1 that is 
conducive to its proteasomal degradation and loss from human PASMC.  Another 
approach might be to produce isoform sub-type SphK1 inhibitors that prevent 
vasoconstriction/vascular remodeling and hypertrophy but yet are able to preserve 
endothelial function to allow unimpeded vasodilation  Alternatively, S1P receptor 
antagonists might represent a viable option for reversing vasoconstriction/vascular 
remodeling in pulmonary hypertension once the receptor (likely S1P2) involved in human 
disease has been identified.  S1P2 antagonists might enable differentiation of action on 
PASMC versus endothelial cells.  Finally, we propose that Degs1 might constitute an 
alternative target because its inhibition has been shown to indirectly promote the 
proteasomal degradation of SphK1 [44].  
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The SphK1 inhibitor, PF-543 also prevents maladaptive hypertrophy in a hypoxic 
mouse model of pulmonary hypertension [33] and cardiac remodeling post myocardial 
infarction [52].  Therefore, we hypothesize that SphK1 might represent an additional target 
for therapeutic intervention in cardiac hypertrophy, with SphK1 inhibitors acting directly 
in the heart to prevent heart failure. Further research should help elucidate the viability of 
these putative targets, and it will be exciting to follow up in these areas of lung and cardiac 
medicine.
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Figure legends 
Figure 1 The role of SphK1/S1P2 in regulating pulmonary vascular remodeling in pulmonary 
hypertension.  The schematic illustrates the role of SphK1 and S1P2 in regulating pulmonary 
arterial smooth muscle proliferation that contributes to vascular remodeling. 
Figure 2 (Key Figure) The opposing roles of SphK1 in regulating vascular smooth muscle 
contractility (possibly via S1P2) and preservation of  endothelial function (possibly via 
S1P1/S1P3) that might suggest more nuanced treatment strategies of pulmonary hypertension 
with SphK1 inhibitors is necessary. 
Figure 3 SphK1 inhibitors induce the ubiquitin-proteasomal degradation of SphK1 in 
PASMC via two distinct mechanisms (direct (PF-543) and indirect (SKi)).  Direct SphK1 
inhibitor-induced proteasomal degradation of SphK1 exhibits resistance under hypoxic 
conditions, while indirect inducers, such as SKi (which also inhibits Degs1) can reduce 
vascular remodeling under hypoxic conditions.   
Figure 4 The role of SphK1 in regulating maladaptive hypertrophy via p53-dependent 
mechanism(s) in pulmonary hypertension. The SphK1 inhibitor, PF-543 reduces maladaptive 
hypertrophy and cardiomyocyte apoptosis in a hypoxic model of pulmonary hypertension.  
This is associated with a PF-543-induced reduction in ventricular p53 levels, which is 
significant as p53 decreases angiogenesis and thereby limits re-oxygenation of the heart. 
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Box 1. Clinician’s Corner  
x There is potential for developing SphK1 inhibitors and S1P receptor antagonists for 
treatment of PAH, but these might require more nuanced approaches to spare 
endothelial function while blocking vasoconstriction/vascular remodeling.  The 
research is at a preclinical stage. 
x Future direction should focus on the development of refined strategies to target 
SphK1, such as development of sub-type inhibitors of SphK1 and/or allosteric 
inhibitors designed to spare endothelial function and block/reverse 
vasoconstriction/vascular remodeling. 
x Biomarker identification is required to determine target engagement and alteration of 
signaling networks that regulate vasoconstriction/vascular remodeling (e.g. S1P 
levels in the blood). This is essential, in order to enable stratification of patients 
groups that are more likely to be responsive to SphK1 inhibitors.  
x Heart failure might be an additional target for therapeutic intervention with SphK1 
inhibitors that act directly on the heart.  Strong collaboration between clinical, basic 
and pharmaceutical scientists is required in order to accelerate the development of 
new S1P therapeutics for the treatment of PAH and heart failure. 

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Trends Box 
x SphK1 expression levels are increased in lungs from hypoxic mouse models of 
pulmonary hypertension and pulmonary arterial hypertensive patients. 
x Increased SphK1 and SphK2 protein expression together with elevated plasma S1P 
levels are also increased in remodelled pulmonary arteries of patients with idiopathic 
pulmonary arterial hypertension and this has been recapitulated in a rat model of 
occlusive pulmonary hypertension. 
x The SphK1 signaling pathway can regulate genes that are either up-regulated or 
down-regulated in PAH, such as RAGE, STAT3 and BMPR2, thereby identifying 
potential overlap with known PAH disease forming mechanisms. 
x SphK1 is involved in hypoxic-dependent pulmonary hypertension, basilar artery 
contraction, Ang II-induced hypertension and subsequent cardiac hypertrophy. 
x S1P formed by SphK1 might be released from arterial smooth muscle cells in an 
autocrine manner to promote proliferation via S1P2 receptors. 
x SphK1 is protective against endothelial dysfunction.  This might reduce effectiveness 
of SphK1 inhibitors in the treatment of PAH. More refined approaches to inhibiting 
SphK1 that enables selective targeting of the enzyme expressed in vascular smooth 
muscle is necessary. 
x SphK1 can become resistant to ubiquitin-proteasomal degradation induced by SphK1 
inhibitors in a hypoxic model of pulmonary hypertension.  More nuanced approaches 
to inhibiting SphK1 that overcome resistance are needed. 
x The SphK1 inhibitor, PF-543 prevents maladaptive hypertrophy in a hypoxic mouse 
model of pulmonary hypertension and cardiac remodeling post myocardial infarction 
suggesting an alternative utility for SphK1 inhibitors acting directly on the heart in 
heart failure. 
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Outstanding Questions 
x Which S1P receptors and SphK1 isoforms play a role in vasoconstriction and 
vasodilation in human pulmonary vessels and are these deregulated in PAH? 
x What are the mechanisms by which SphK1 and S1P receptors regulate cellular 
signaling pathways involving RAGE, STAT3 and BMPR2 in humans and are these 
critical to the development of PAH? 
x What is the major function of SphK1 in PAH with respect to its role in regulating 
vascular smooth muscle contractility, vascular remodeling and protecting against 
endothelial dysfunction? 
x Is there a role for SphK1 in promoting inflammatory responses underlying changes 
in vascular function and remodeling in PAH 
x What is the mechanism that endows SphK1 with resistance to inhibitor-induced 
ubiquitin-proteasomal degradation in hypoxic induced pulmonary hypertension and 
is this evident in other models of PAH? 
x Can refined strategies to target SphK1/S1P be developed to allow effective 
intervention in PAH? 
x Can SphK1 inhibitors be developed that target different SphK1 sub-types to 
prevent/reverse vascular remodeling and hypertrophy but spare endothelial protective 
mechanism? 

 
 
1

Glossary 
aortic ring:  a transverse section of the aorta, used to measure vascular function in vitro 
BMPR2: Bone morphogenetic protein receptor type 2 is a serine/threonine receptor 
kinase that binds bone morphogenetic proteins (BMPs), members of the transforming growth 
factor ligand family, and signals through intracellular SMAD proteins to activate 
transcription. 
cardiac index (CI):  a measure of cardiac function, calculated by dividing cardiac output by 
body weight. 
Degs1:  Dihydroceramide desaturase; an enzyme that catalyses the synthesis of ceramide 
from dihydroceramide. 
HIF1Į:  Hypoxic inducible factor 1 alpha transcriptional factor is a master transcriptional 
regulator of genes in response to hypoxia. 
HIF2Į:  Hypoxic inducible factor 2 alpha transcriptional factor. 
hypoxic-induced pulmonary hypertensive: high blood pressure in the pulmonary arteries, 
arising due to a chronic deficiency of oxygen. 
idiopathic pulmonary arterial hypertension (IPAH):  an elevation of pulmonary artery 
pressure with no apparent cause. 
inside-out signaling:  the release of chemical signals from cells which then act in an 
autocrine (on the same cell) or paracrine (on a different cell) manner. 
maladaptive hypertrophy:  a pathological thickening of the heart wall that precedes heart 
failure. 
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Nogo B:  a protein of the endoplasmic reticulum which inhibits serine palmitoyltransferase 
(the rate-limiting enzyme of de novo ceramide biosynthesis) (also known as Reticulon 4B) 
Nrf-2:  Regulates transcription of anti-oxidant proteins that protect against oxidative stress. 
occlusive pulmonary hypertension:  hypertension arising from blockage of the pulmonary 
veins. 
occlusive pulmonary arteriopathy:  disease of the pulmonary arteries resulting in their 
blockage. 
p53:  tumor protein p53, which functions as a tumor suppressor. 
PARP:  poly (ADP-ribose) polymerase enzymes; involved in DNA repair and programmed 
cell death. 
portal hypertension:  high blood pressure in the hepatic portal system. 
pressure overload:  a pathological state where the heart muscle contracts against an 
excessive aortic pressure; chronic pressure overload can lead to cardiac hypertrophy.   
RAGE:  a transmembrane receptor for advance glycation end-products (glycated lipids and 
proteins) and damage-associated molecular pattern molecules. 
right ventricular internal diameter (RVID):  the inner diameter of the right ventricle. 
right ventricular systolic pressure (RVSP):  the peak of pulmonary artery pressure. 
right ventricular hypertrophy (RVH):  thickening of the right ventricle wall. 
sinusoidal vasoconstriction:  a reduction in the diameter of the sinusoidal blood vessels of 
the liver 
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STAT3:  a transcription factor that is a member of the Signal Transducer Activator of 
Transcription family; it is activated in response to various cytokines through Janus kinase-
catalysed phosphorylation, followed by homo- or hetero-dimerisation.   
Sugen5416/hypoxia/normoxia (Su/Hx/Nx PAH):  an animal model of pulmonary 
hypertension that is induced by the combination of a vascular endothelial growth factor 
receptor antagonist, Sugen 5416 (SU5416) and chronic hypoxia. 
total pulmonary artery resistance index (TPRI):  a measure of pulmonary artery 
resistance, calculated by dividing RVSP by CI. 
vascular remodelling:  altered structure of resistance vessels giving rise to increased 
systemic vascular resistance in hypertension.
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